Banking of pluripotent adult stem cells as an unlimited source for red blood cell production: potential applications for alloimmunized patients and rare blood challenges.

摘要: The transfusion of red blood cells (RBCs) is now considered a well-settled and essential therapy. However, some difficulties constraints still occur, such as long-term product shortage, donor population aging, known yet unknown transfusion-transmitted infectious agents, growing cost the supply chain management, inescapable group polymorphism barrier. Red can be cultured in vitro from human hematopoietic, embryonic, or human-induced pluripotent stem (hiPSCs). highly promising hiPSC technology represents potentially unlimited source RBCs opens door to revolutionary development new generation allogeneic products. Assuming that large-scale RBC production efficiently operates near future, we draw here futuristic but realistic scenarios regarding potential applications for alloimmunized patients those with rare group. We retrospectively studied cohort 16,486 consecutive (10-year period), showing 1 7 alloantibodies 361 different antibody combinations. showed only 3 clones would sufficient match more than 99% need transfusions. study French National Registry People Rare Blood Phenotype/Genotype period) shows 15 cover 100% needs white ancestry. In addition, one single clone meet 73% sickle cell disease whom cryopreserved units were required. As result, consider very limited number able not provide most also allow policy alloimmunization prevention multiply transfused patients.